2.10
-0.08(-3.67%)
Currency In USD
Address
11400 West Olympic Boulevard
Los Angeles, CA 90064
United States of America
Phone
310 651 8041
Website
Sector
Healthcare
Industry
Biotechnology
Employees
14
First IPO Date
December 16, 2021
| Name | Title | Pay | Year Born |
| Dr. Ilya Rachman M.B.A., M.D., MBA, Ph.D. | Co-Founder, Chief Executive Officer & Chairman | 669,000 | 1973 |
| Dr. Graham Ross FFPM, M.D. | Chief Medical Officer & Head of Clinical Development | 104,423 | 1960 |
| Mr. Gabriel Morris B.A. | Chief Financial Officer & Director | 669,000 | 1987 |
| Mr. Sean Senn J.D., M.B.A., M.Sc., MBA, MSc | Co-Founder | 0 | N/A |
| Mr. Nandan Oza B.S. | Head of Chemistry, Manufacturing & Control | 0 | 1962 |
| Dr. Vladimir P. Torchilin D.Sc., MSE, Ph.D. | Scientific Co-Founder | 0 | 1947 |
| Mr. Gerhard Bauer | Head of Cell Therapy Manufacturing | 0 | N/A |
| Dr. David Marks | Chief Medical Officer of Cell Therapy | 0 | N/A |
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing various tissue-specific therapeutics in oncology and inflammation in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and solid tumors; IMX-111, a tissue-specific biologic for the treatment of colorectal cancers; and IMX-120, a tissue-specific biologic for the treatment of ulcerative colitis and severe Crohn's disease. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. The company was incorporated in 2012 and is headquartered in Los Angeles, California.